Table 1.

Inclusion/Exclusion Criteria for Study Selection

Study Criteria	Patients	Interventions	Comparators	Outcomes	Study Design	Time Frame
Inclusion	Studies evaluating hospitalized adult patients with confirmed or suspected HABP/VABP, cUTIs, bacteremia, or cIAI attributable to CRE pathogens	All antibiotics considered	Any antibiotic	Mortality Infection-related mortality Reinfection Readmission Length of hospital stay Length of ICU stay Any economic outcome Adverse events	Observational studies (prospective/ retrospective) Randomized trials Nonrandomized trials	Studies published between January 1, 1994, and December 1, 2015
Exclusion	Studies evaluating patients without CRE infections Studies not reporting separable outcomes for patients with HABP/VABP, cUTIs, bacteremia, or cIAI Studies evaluating pediatric patients Studies of patients with community- acquired infections Studies evaluating patients treated in the outpatient setting	Treatments other than antibiotics		Studies not reporting clinical or economic outcomes related to CRE infections of interest	Animal, in vitro, or genetic studies; narrative publications, nonsystematic reviews, case studies, case reports, and editorials; comparative studies with <10 patients per treatment group in ≥2 treatment arms or single-arm studies with ≤20 patients	Studies published before 1994 or after December 1, 2015

Abbreviations: cIAI, complicated intra-abdominal infection; CRE, carbapenem-resistant Enterobacteriaceae; cUTI, complicated urinary tract infection; HABP/VABP, hospital-acquired and ventilator-associated bacterial pneumonia; ICU, intensive care unit.